Response Assessment Criteria for Glioblastoma: Practical Adaptation and Implementation in Clinical Trials of Antiangiogenic Therapy

Assessment of intra-observer variability in measurement of high-grade brain tumors

(2012) James M. Provenzale et al.   JOURNAL OF NEURO-ONCOLOGY

Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria

(2012) J. G. Perez-Larraya et al.   NEURO-ONCOLOGY

AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme

(2011) O. L. Chinot et al.   ADVANCES IN THERAPY

Pseudoprogression and Pseudoresponse: Imaging Challenges in the Assessment of Posttreatment Glioma

(2011) L.C. Hygino da Cruz et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

The CareGiver Oncology Quality of Life questionnaire (CarGOQoL): Development and validation of an instrument to measure the quality of life of the caregivers of patients with cancer

(2011) Patricia Minaya et al.   EUROPEAN JOURNAL OF CANCER

Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study

(2011) John F. de Groot et al.   JOURNAL OF CLINICAL ONCOLOGY

Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas

(2011) MJ van den Bent et al.   LANCET ONCOLOGY

Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide

(2011) M.-Y. C. Polley et al.   NEURO-ONCOLOGY

Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice

(2011) J. F. de Groot et al.   NEURO-ONCOLOGY

Clinical trial end points for high-grade glioma: the evolving landscape

(2011) D. A. Reardon et al.   NEURO-ONCOLOGY

Application of Novel Response/Progression Measures for Surgically Delivered Therapies for Gliomas

(2011) Michael A. Vogelbaum et al.   NEUROSURGERY

Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma

(2011) Olivier Keunen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

(2010) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

Radiographic patterns of relapse in glioblastoma

(2010) Marc C. Chamberlain   JOURNAL OF NEURO-ONCOLOGY

Evaluation of diffusion parameters as early biomarkers of disease progression in glioblastoma multiforme

(2010) I. S. Khayal et al.   NEURO-ONCOLOGY

Response Assessment in Neuro-Oncology

(2010) Eudocia C. Quant et al.   Current Oncology Reports

Pseudoprogression and pseudoresponse in the treatment of gliomas

(2009) Dieta Brandsma et al.   CURRENT OPINION IN NEUROLOGY

End Point Assessment in Gliomas: Novel Treatments Limit Usefulness of Classical Macdonald's Criteria

(2009) Martin J. van den Bent et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

(2009) Henry S. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

Tumor regrowth between surgery and initiation of adjuvant therapy in patients with newly diagnosed glioblastoma

(2009) Andrea Pirzkall et al.   NEURO-ONCOLOGY

Brain Tumor Imaging in Clinical Trials

(2008) J.W. Henson et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

Incidence of early pseudo‐progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide

(2008) Walter Taal et al.   CANCER

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

MGMTPromoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression After Concomitant Radiochemotherapy in Newly Diagnosed Glioblastoma Patients

(2008) Alba A. Brandes et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma

(2008) Teri N. Kreisl et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence

(2008) A. D. Norden et al.   NEUROLOGY

Malignant Gliomas in Adults

(2008) Patrick Y. Wen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Response criteria for glioma

(2008) A Gregory Sorensen et al.   Nature clinical practice. Oncology